Last reviewed · How we verify
NCT06864572
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
EARLY_PHASE1 trial testing P17-079, P16-093, or P15-041 PET/CT in Metastatic Prostate Cancer (mPC) in 40 participants. Enrolling by invitation.
1 September 2026
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 40 |
| Start date | 1 September 2024 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- P17-079, P16-093, or P15-041 PET/CT
Conditions studied
- Metastatic Prostate Cancer (mPC) — all drugs for Metastatic Prostate Cancer (mPC) →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 85, male only, with Metastatic Prostate Cancer (mPC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Preclinical studies have confirmed that \[68Ga\]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables \[68Ga\]Ga-P17-079 to be fully absorbed by the lesions, and it is possible to detect bone metastases, prostate cancer primary sites, lymph node metastases and organ metastases at the same time in a single examination. It is a potential "killing two birds with one stone" imaging agent. At this stage, the clinical study of \[68Ga\]Ga-P17-079 in the diagnosis and treatment of metastatic prostate cancer as a self-made preparation is planned to be carried out in our hospital to further verify its clinical application value.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06864572
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Prostate Cancer (mPC)
Currently open trials in the same condition.
- NCT06762379 — Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration · recruiting
- NCT06866782 — European Registry of Next Generation Imaging in Advanced Prostate Cancer · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06864572 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06864572.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing